Biopharma Pulse - 5/16-5/20 Week in Review
As we have reached the middle of May, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move (5/9-5/13) | YTD Move |
|---|---|---|
All BPIQ Companies | +2.18% | -45.87% |
CAR-T Companies | +4.58% | -46.28% |
Gene Editing Companies | +2.99% | -53.45% |
XBI | +2.52% | -37.18% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week of 5/16-5/20
Biggest positive move
$BMEA +69.4% Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
Biggest negative move
$EVFM -64.0% Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering
Additional big moves
$RVVTF +66.7% Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
$SIGA +66.2% SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
$CRBP +61.9%
$IDRA +48.6% Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
$IMNM +47.3% Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
$CALT +38.9% Calliditas receives positive CHMP opinion in IgA nephropathy
$PCSA +35.9% Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
$ACRX +27.6% AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
$CALT +18.0% Calliditas receives positive CHMP opinion in IgA nephropathy
$SIGA +17.1% SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat
$IDRA +16.0% Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
$GRTX +13.3% Galera Announces Plan to Submit Avasopasem NDA by Year End
$CRDL +11.0% Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis.
$INAB -11.4% IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform.
$TNXP -13.1% Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2
$CABA -13.3% Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting
$KROS -16.6% Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers.
$ENTA -17.3% Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
$AMTI -18.5% Applied Molecular Transport Provides Strategy Update.
$APRE -19.1% Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
$VALN -20.6% Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement
$FHTX -25.8% Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
$TNXP -39.7% Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
$CMRX -44.6% Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
$ATHX -55.2% Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study.
$ENDP -60.8% Drugmaker Endo Begins Debt-Restructuring Talks With Creditors Amid Opioid Litigation
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
$VRCA VP-102 PDUFA target action date
See our Big Movers post to learn about upcoming Movers throughout May and PDUFAs, after subscribing. Learn more here.
Comments